Immunocore Limited announced that Bahija Jallal has been appointed as Chief Executive Officer and Director of the Board. With more than 25 years of international leadership experience within the pharmaceutical industry, Bahija joins Immunocore from AstraZeneca, where she is President of MedImmune, its global biologics research and development arm, and a member of the senior executive team reporting to the CEO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.69 USD | -0.84% | -8.61% | -37.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.51% | 215.3Cr | |
+43.64% | 75TCr | |
+39.42% | 61TCr | |
-6.58% | 35TCr | |
+19.72% | 33TCr | |
+8.78% | 29TCr | |
+11.92% | 22TCr | |
-2.62% | 21TCr | |
+0.03% | 17TCr | |
+6.13% | 16TCr |
- Stock Market
- Equities
- IMCR Stock
- News Immunocore Holdings plc
- Immunocore Limited Appoints Bahija Jallal as Chief Executive Officer and Director of the Board